Resource Summary Report

Generated by NIF on Aug 1, 2026

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb

RRID:AB_2315112
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4370, RRID:AB_2315112)

Antibody Information

URL: http://antibodyregistry.org/AB_2315112

Proper Citation: (Cell Signaling Technology Cat# 4370, RRID:AB_2315112)

Target Antigen: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IP, IHC-P, IF-IC, FC-FP
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE
Consolidation on 9/2016: AB_2297462, AB_10234795, AB_2281741

Antibody Name: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb

Description: This recombinant monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Target Organism: monkey, rat, hamster, mink, pig, mouse, bovine, zebrafish, human, dog

Clone ID: D13.14.4E

Defining Citation: PMID:22237807, PMID:23602964

Antibody ID: AB_2315112

Vendor: Cell Signaling Technology

Catalog Number: 4370

Alternative Catalog Numbers: 4370L, 4370T, 4370P, 4370S

Record Creation Time: 20260218T230855+0000

Record Last Update: 20260225T232814+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 1024 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Rosen JC, et al. (2026) Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. British journal of cancer, 134(1), 165.

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Yan X, et al. (2026) KRASG12/13 mutation modulates CRC outcomes via disrupting positive feedback between macrophage and CD4+ T cell. iScience, 29(1), 114402.

Lu P, et al. (2026) Bromodomain-containing protein 4 knockdown promotes neuronal ferroptosis in a mouse model of subarachnoid hemorrhage. Neural regeneration research, 21(2), 715.

Fan H, et al. (2026) Dynamic control of Raf-ERK signaling modulates neuronal activity across biological scales. bioRxiv : the preprint server for biology.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Molecular cell, 86(1), 60.

Özel C, et al. (2026) Mitochondrial integrity modulates mTOR signaling and podocyte function. iScience, 29(1), 114279.

Stanland LJ, et al. (2026) Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches. STAR protocols, 7(1), 104323.

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. Cancer cell.

Wu ZY, et al. (2025) Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors. Cancer cell, 43(9), 1714.

Kesh K, et al. (2025) Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models. Cancers, 17(14).

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Guo D, et al. (2025) OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth. Molecular cell, 85(4), 843.

Huang W, et al. (2025) Deficiency of fibroblast growth factor 2 promotes contractile phenotype of pericytes in ascending thoracic aortic aneurysm. American journal of physiology. Heart and circulatory physiology, 328(5), H1130.

Koundouros N, et al. (2025) Direct sensing of dietary ?-6 linoleic acid through FABP5-mTORC1 signaling. Science (New York, N.Y.), 387(6739), eadm9805.

Zhou K, et al. (2025) Antagonistic systemin receptors integrate the activation and attenuation of systemic wound signaling in tomato. Developmental cell, 60(4), 535.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral ??T-cell Activity. Cancer research, 85(2), 277.

Danos JA, et al. (2025) Nerve Growth Factor Signaling Tunes Axon Maintenance Protein Abundance and Kinetics of Wallerian Degeneration. bioRxiv : the preprint server for biology.

Lou L, et al. (2025) VCPIP1 potentiates innate immune responses by non-catalytically reducing the ubiquitination of IRAK1/2. Cell reports, 44(7), 115931.